Olaris is founded on the belief that collaborative research will lead to breakthrough science with the potential to transform human health. Contact us to learn about collaboration opportunities.
THERMO FISHER SCIENTIFIC is a world leader in serving science, supporting revolutionary researchers who are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, and developing and manufacturing of life-changing therapies. Olaris has partnered with Thermo Fisher Scientific to evaluate a diagnostic to assess the risk of developing complications from overimmunosuppression in kidney transplant recipients based on a metabolomics signature discovered via Olaris’ platform. Olaris and Thermo Fisher share a mutual goal of improving patients' lives post-transplant.
THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH (MJFF) is a non-profit dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. MJFF has issued a grant to Olaris, Inc to identify metabolic signatures associated with the neurodegenerative disease. Metabolic signatures may provide deeper insight into the mechanisms involved in Parkinson’s and its progression. Our mutual goal is to advance our understanding of this disease and find potential drug targets for future therapies.
CARAWAY THERAPEUTICS is developing small molecules to treat neurodegenerative and rare diseases by selectively targeting the autophagy pathway. Autophagy is a biological process that degrades long‐lived proteins, including damaged organelles and toxic aggregates, and is fundamental to maintaining healthy cellular homeostasis; dysregulation of autophagy is hypothesized to lead to neurodegeneration. Olaris is working with Caraway in their pre-clinical and clinical programs.
LOULOU FOUNDATION is a non-profit dedicated to advancing research into the understanding and development of therapeutics for CDKL5 deficiency disorder. Olaris is a proud partner with the Loulou Foundation. Olaris uses our technology to determine metabolic differences between CDKL5 wild-type and mutant neurons derived from patients. The Olaris metabolite readout will increase the biological understanding of CDKL5 function. Further it could lead to downstream therapeutic targets and pharmacodynamic endpoints to screen therapies and de-risk and accelerate approval of novel and needed therapies for CDKL5 deficiency.